This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Jerome Mettetal and His Patent on a B-Cell Malignancy Treatment
Introduction
Jerome Mettetal is an inventor based in Waltham, Massachusetts, and is associated with AstraZeneca AB. His work includes a patent concerning a combination therapy for B-cell malignancies.
Latest Patents
Mettetal is named on 1 patent: “Therapeutic Combinations of Acalabrutinib and Capivasertib to Treat B-Cell Malignancies.” The patent describes using acalabrutinib and capivasertib, or their pharmaceutically acceptable salts, to treat, prevent, or alleviate B-cell malignancies, including non-Hodgkin’s lymphoma. It also covers pharmaceutical compositions and kits containing the two medicines.
Career Highlights
Mettetal’s listed patent work focuses on therapeutic combinations intended to address B-cell malignancies. The invention describes potential applications for patients in need of treatment.
Collaborations
Brandon Willis and Andrew Bloecher are identified as Mettetal’s coworkers. Their names are associated with the professional context provided for his work.
Conclusion
Jerome Mettetal’s patent contribution centers on combining acalabrutinib and capivasertib, with related compositions and kits, for potential use against B-cell malignancies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile